Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
ILMN Illumina Inc. monthly Stock Chart
Illumina Inc.
IndexS&P 500 P/E53.62 EPS (ttm)3.43 Insider Own1.00% Shs Outstand146.40M Perf Week5.48%
Market Cap26.92B Forward P/E48.79 EPS next Y3.77 Insider Trans-24.77% Shs Float145.05M Perf Month26.20%
Income510.40M PEG2.73 EPS next Q0.79 Inst Own93.10% Short Float3.53% Perf Quarter-6.94%
Sales2.14B P/S12.58 EPS this Y163.30% Inst Trans0.75% Short Ratio2.09 Perf Half Y-10.38%
Book/sh13.32 P/B13.81 EPS next Y14.11% ROA14.30% Target Price182.61 Perf Year-3.66%
Cash/sh9.83 P/C18.70 EPS next 5Y19.61% ROE30.00% 52W Range130.00 - 242.37 Perf YTD-0.37%
Dividend- P/FCF69.44 EPS past 5Y34.90% ROI15.20% 52W High-24.12% Beta0.70
Dividend %- Quick Ratio3.40 Sales past 5Y22.80% Gross Margin71.20% 52W Low41.46% ATR5.79
Employees3700 Current Ratio3.80 Sales Q/Q14.50% Oper. Margin31.40% RSI (14)71.87 Volatility2.92% 3.33%
OptionableYes Debt/Eq0.57 EPS Q/Q25.40% Profit Margin23.80% Rel Volume0.79 Prev Close185.56
ShortableYes LT Debt/Eq0.52 EarningsOct 20 AMC Payout0.00% Avg Volume2.44M Price183.90
Recom2.10 SMA2012.01% SMA5014.04% SMA200-4.61% Volume1,908,500 Change-0.89%
Oct-13-15Reiterated Barclays Equal Weight $215 → $170
Oct-06-15Reiterated Stifel Buy $235 → $175
Oct-06-15Reiterated Piper Jaffray Overweight $230 → $220
Oct-06-15Reiterated Leerink Partners Mkt Perform $185 → $155
Oct-06-15Reiterated Goldman Neutral $230 → $137
Oct-06-15Downgrade Mizuho Buy → Neutral $250 → $150
Oct-01-15Downgrade Leerink Partners Outperform → Mkt Perform
Aug-27-15Initiated Cantor Fitzgerald Buy
Aug-19-15Reiterated Mizuho Buy $240 → $250
Jul-22-15Reiterated Mizuho Buy $230 → $240
Jul-22-15Reiterated Canaccord Genuity Buy $275 → $250
May-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $162 → $190
Apr-22-15Reiterated Mizuho Buy $220 → $230
Mar-10-15Initiated UBS Buy $240
Jan-28-15Reiterated Stifel Buy $215 → $235
Jan-28-15Reiterated Maxim Group Buy $236 → $255
Jan-07-15Initiated Barclays Equal Weight $210
Oct-27-14Reiterated Stifel Buy $200 → $215
Oct-21-14Reiterated ISI Group Neutral $175 → $180.50
Aug-12-14Initiated Stifel Buy $200
Dec-01-15 12:03AM  Hedge Funds Are Betting On Exelon Corporation (EXC) at Insider Monkey
Nov-30-15 10:45AM  Is Illumina, Inc. (ILMN) A Good Stock To Buy? at Insider Monkey
Nov-24-15 02:47PM  Should You Follow Smart Money Into Vertex Pharmaceuticals Incorporated (VRTX)? at Insider Monkey
Nov-23-15 12:47PM  Mylan Topped Large-Caps with New Launches, Share Repurchase Plan
Nov-22-15 10:21AM  5 Stocks Hedge Funds Hated in the Third Quarter at TheStreet
Nov-19-15 03:03PM  Why Pacific Biosciences of California Is Soaring Higher Today at Motley Fool
Nov-18-15 08:06AM  Illumina Continued to Rise, Led the Large-Cap Stocks
Nov-17-15 01:20PM  Illumina attracts show of support
Nov-16-15 08:00AM  Illumina (ILMN) in Focus: Stock Adds 6.6% in Session
Nov-14-15 09:40AM  Why Being Added into the S&P 500 Matters So Much for Illumina at 24/7 Wall St.
Nov-13-15 05:40PM  Working Opportunity Fund Declares Venture Series Cash Dividend and Provides Portfolio Update CNW Group +6.60%
02:50PM  Illumina (ILMN) Set to Enter the Coveted S&P 500, Stock Up
01:24PM  Illumina (ILMN) Stock Advances Ahead of Joining S&P 500 at TheStreet
01:18PM  The Stock Leading the Genomics Revolution
10:01AM  Illumina Set To Join S&P 500, Replacing Sigma-Aldrich at
Nov-12-15 06:44PM  Illumina Set to Join the S&P 500 PR Newswire
09:18AM  Why Pacific Biosciences of California Jumped 30% in October at Motley Fool
Nov-11-15 08:00AM  Mohr Davidow Ventures Focuses on Closing the Gender Gap in Technology With a Private Screening of CodeGirl and Panel Discussion Marketwired
Nov-06-15 01:04PM  ILLUMINA INC Financials
Nov-05-15 10:19AM  Illumina Led IBBs Large-Cap Portfolio
Nov-03-15 04:41PM  Don't Allow A Healthy Winner To Turn Into A Loser at Investor's Business Daily
Nov-02-15 04:32PM  ILLUMINA INC Files SEC form 10-Q, Quarterly Report
06:30AM  Illumina Announces New $250 Million Share Repurchase Authorization Business Wire
Nov-01-15 03:20PM  Qiagen NV Earnings: Just What You'd Expect at Motley Fool
Oct-27-15 03:05PM  Why Pacific Biosciences of California Went Up, Then Down, Then Sideways at Motley Fool
01:25PM  Illumina, Inc. Value Analysis (NASDAQ:ILMN) : October 27, 2015
Oct-25-15 01:40PM  Is Profitiablity in Pacific Biosciences of California's DNA? at Motley Fool
10:01AM  Illumina Inc. Reports Disappointing Q3 Sales at Motley Fool
Oct-23-15 12:54PM  Why Pacific Biosciences of California Jumped Today at Motley Fool
10:54AM  Talking Earnings Season With Estimize
Oct-22-15 02:41PM  Clarification: Earns-Illumina story
10:45AM  Illumina, Inc. Earnings Q3, 2015
Oct-21-15 12:50PM  6 Key Analyst Downgrades From Wednesday That Cannot Be Overlooked at 24/7 Wall St.
10:14AM  Illumina (ILMN) Stock Price Target Slashed at Canaccord After Earnings Results at TheStreet
09:36AM  What is Going On With These Four Stocks in the Spotlights? at Insider Monkey
09:15AM  Illumina Tops Q3 Earnings, Meets Revenues; '15 View Cut
04:18AM  Edited Transcript of ILMN earnings conference call or presentation 20-Oct-15 9:00pm GMT
Oct-20-15 06:23PM  Illumina (ILMN) Beats on Earnings, Meets Revenue Estimate
05:00PM  Illumina Inc Earnings Call scheduled for 5:00 pm ET today
04:54PM  [$$] Illumina Posts Higher Profit at The Wall Street Journal
04:29PM  Illumina (ILMN) Stock Slides in After-Hours Trading on Revenue Miss at TheStreet
04:22PM  Illumina tops 3Q profit forecasts
04:09PM  ILLUMINA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Illumina Reports Financial Results for Third Quarter of Fiscal Year 2015 Business Wire
07:07AM  Q3 2015 Illumina Inc Earnings Release - After Market Close
Oct-16-15 04:45PM  Illumina (ILMN) Q3 Earnings: Is a Disappointment in Store?
10:08AM  The reasons to be bearish are actually reasons to be bullish at MarketWatch
Oct-14-15 04:31PM  Funding values genetics company 23andMe at $1.1 billion Reuters
Oct-13-15 12:58PM  [Podcast] The broad themes you need to know going into earnings season - from commodities to housing to biotech
Oct-08-15 04:13PM  Illumina (ILMN) Stock Could Light Up, Reversal in the Works at TheStreet
09:08AM  IBB and XBIs Top 10 Large-Cap Stocks Underperform
Oct-07-15 04:45PM  Illumina Sales Disappoint, Will Continue to Do So at Investopedia
03:59PM  Why Pacific Biosciences Pushed Higher Today at Motley Fool
01:00PM  Becton, Dickinson Launches FACSseq Single Cell Sorter
10:55AM  Illumina Fell 10.6% on a Biotech Sell-Off
08:25AM  Illumina (ILMN): Moving Average Crossover Alert
06:30AM  Illumina Introduces Genomics Solutions to Advance Clinical Research Business Wire
Oct-06-15 07:13PM  Dow ETF Cushioned By DuPont; Biotech Sell-Off Thickens at Investor's Business Daily -10.64%
04:39PM  Illumina Downgraded; Apple Supplier Skyworks PT Cut at Investor's Business Daily
04:38PM  Stocks Close Mixed as Biotech Slumps, Energy Jumps at TheStreet
04:20PM  Illumina (ILMN) Shares Tumble on Weak Outlook for Sales
04:04PM  The 52-Week Low Club for Tuesday
03:01PM  Biotechs take a beating
01:01PM  Videocast: Volatility levels decline
12:38PM  What's Wrong With Health Care? at
12:26PM  Why Illumina Is Down Big Today at Motley Fool
11:46AM  DuPont Cushions Dow; Chip Stocks, Biotechs Weigh On Nasdaq at Investor's Business Daily
11:08AM  Big put sale sees floor in Illumina
10:45AM  Things Look Dark at Illumina at
10:36AM  Stocks Move Back Into Red as Biotech Sells Off Again at TheStreet
10:35AM  Stocks Wrestle In Mixed Action; DuPont Surges, Illumina Dives at Investor's Business Daily
10:13AM  More Pain For Biotech ETFs at
09:39AM  Illumina plummets after weak guidance
09:35AM  Heres Why These Three After-Market Lemons May Be Good Buys On The Dip at Insider Monkey
09:30AM  Edited Transcript of ILMN earnings conference call or presentation 5-Oct-15 8:30pm GMT
09:22AM  Cramer's Mad Dash: PMCS & SWKS
09:14AM  Stock Futures Down, Off Lows On News From DuPont, Pepsi, Illumina at Investor's Business Daily
09:03AM  Illumina (ILMN) Stock Continues Tumble on Sales Outlook at TheStreet
08:50AM  Top Analyst Upgrades and Downgrades: CBS, Cisco, Comerica, Twitter, FedEx, Illumina, Linn, NuVasive and Many More at 24/7 Wall St.
07:49AM  Early movers: PEP, ABC, DD, CSCO, BABA & more at CNBC
06:30AM  Illumina Expands Use of HiSeq X Sequencing System to Include Non-Human Species Business Wire
Oct-05-15 09:32PM  Trending Now: ILMN
05:26PM  Monday's After-Hours Movers Led By Du Pont, Arena Pharma, Illumina & Container Store Group
05:20PM  After-hours buzz: Illumina, DuPont & more at CNBC
05:07PM  Illumina Stock Dives On Latest Sales Warning at Investor's Business Daily
04:55PM  Illumina Poised on Product Innovation, Global Expansion
04:54PM  Illumina (ILMN) Stock Plummets in After-Hours Trading on Guidance at TheStreet
04:30PM  Mohawk Industries Inc Earnings Call scheduled for 4:30 pm ET today
04:25PM  Illumina Plunges 16% as Sales Slump at
04:08PM  ILLUMINA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Illumina Announces Preliminary Revenue for Third Quarter of Fiscal Year 2015 Business Wire
08:02AM  Genomics Out Of 'Caveman Era,' But Still A Ways To Go at Investor's Business Daily
Oct-02-15 02:40PM  Illumina Downgraded by Leerink, Shares Plummet Over 10%
08:50AM  Weakness Seen in Illumina Inc. (ILMN): Stock Tumbles 10.6%
Oct-01-15 03:43PM  Illumina Tumbles On Downgrade, New Competition at Investor's Business Daily -10.58%
03:39PM  Why Illumina Fell Today at Motley Fool
02:23PM  Pacific Biosciences Has 'Long Road' Ahead, But Cantor Still Bullish
11:57AM  How Do Hedge Funds View These 3 Downgraded Stocks? at Insider Monkey
10:58AM  Stocks Give Up Early Gains As Apple, Illumina, Sucampo Slide at Investor's Business Daily
07:55AM  Analysts' Actions -- Allergan, Microsoft, Universal Health, World Wrestling Entertainment and More
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company's products include sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms consist of HiScan and iScan systems, as well as NextSeq 550 system that are array scanners for DNA and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis. It also offers various library preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping, noninvasive prenatal test, and whole-genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. It has a collaboration agreement with Merck Serono to develop a sequencing-based oncology diagnostic; Burning Rock to develop molecular diagnostics for oncology; and Memorial Sloan Kettering Cancer Center to develop of strategies to diagnose and monitor cancer, and establish ctDNA as an important marker in the study and eventual treatment of cancer. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dadswell CharlesSr VP & General CounselNov 27Sale180.7216930,54240,553Nov 30 05:38 PM
EPSTEIN ROBERT SDirectorNov 27Sale185.561,000185,5606,935Nov 30 05:41 PM
FLATLEY JAY TChief Executive OfficerNov 25Option Exercise27.975,000139,850428,793Nov 27 09:52 AM
FLATLEY JAY TChief Executive OfficerNov 25Sale180.005,000900,000423,793Nov 27 09:52 AM
FLATLEY JAY TChief Executive OfficerNov 24Option Exercise27.9720,000559,400443,793Nov 25 01:56 PM
FLATLEY JAY TChief Executive OfficerNov 24Sale173.2720,0003,465,342423,793Nov 25 01:56 PM
FLATLEY JAY TChief Executive OfficerNov 16Option Exercise27.9710,000279,700433,793Nov 17 08:29 PM
FLATLEY JAY TChief Executive OfficerNov 16Sale170.0010,0001,700,000423,793Nov 17 08:29 PM
Klausner RichardSr VP, Chief Medical OfficerNov 13Sale163.52730119,37023,100Nov 16 05:16 PM
BRADBURY DANIELDirectorNov 10Option Exercise44.511,70075,66716,076Nov 12 07:42 PM
BRADBURY DANIELDirectorNov 10Sale154.031,700261,84614,376Nov 12 07:42 PM
WALT DAVID RDirectorNov 10Sale154.032,000308,06436,960Nov 12 09:22 PM
Dadswell CharlesSr VP & General CounselNov 03Sale150.0015823,70040,847Nov 04 05:44 PM
FLATLEY JAY TChief Executive OfficerOct 15Option Exercise27.9710,000279,700434,996Oct 16 09:10 PM
FLATLEY JAY TChief Executive OfficerOct 15Sale150.0010,0001,500,000424,996Oct 16 09:10 PM
BRADBURY DANIELDirectorOct 07Option Exercise44.511,70075,66716,076Oct 07 07:46 PM
BRADBURY DANIELDirectorOct 07Sale145.811,700247,87814,376Oct 07 07:46 PM
WALT DAVID RDirectorSep 29Sale171.652,000343,29438,960Oct 01 05:47 PM
Dadswell CharlesSr VP & General CounselSep 28Sale173.2015727,19241,005Sep 28 07:11 PM
Klausner RichardSr VP, Chief Medical OfficerSep 28Sale173.2042373,26424,016Sep 29 04:26 PM
FLATLEY JAY TChief Executive OfficerSep 22Option Exercise27.9725,000699,250449,996Sep 23 12:42 PM
FLATLEY JAY TChief Executive OfficerSep 22Sale192.7925,0004,819,681424,996Sep 23 12:42 PM
WALT DAVID RDirectorSep 15Sale206.452,000412,89440,960Sep 17 07:39 PM
Bianchi Paul LSr. VP, Human ResourcesSep 09Sale199.321,245248,15358,519Sep 10 06:02 PM
FLATLEY JAY TChief Executive OfficerSep 08Option Exercise27.9725,000699,250449,996Sep 08 05:57 PM
EASTHAM KARINDirectorSep 08Option Exercise44.514,300191,39314,719Sep 08 06:02 PM
FLATLEY JAY TChief Executive OfficerSep 08Sale194.8725,0004,871,849424,996Sep 08 05:57 PM
EASTHAM KARINDirectorSep 08Sale195.764,300841,76810,419Sep 08 06:02 PM
WHITFIELD ROY ADirectorSep 04Option Exercise36.294,500163,30518,148Sep 09 07:56 PM
WHITFIELD ROY ADirectorSep 04Sale192.634,500866,83513,648Sep 09 07:56 PM
WALT DAVID RDirectorSep 01Sale195.082,000390,15142,960Sep 01 05:44 PM
FLATLEY JAY TChief Executive OfficerAug 27Option Exercise27.9725,000699,250449,996Aug 31 06:01 PM
Dadswell CharlesSr VP & General CounselAug 27Sale198.8116332,40641,162Aug 31 05:34 PM
FLATLEY JAY TChief Executive OfficerAug 27Sale200.1625,0005,004,125424,996Aug 31 06:01 PM
WALT DAVID RDirectorAug 18Sale206.892,000413,78544,960Aug 19 06:55 PM
BRADBURY DANIELDirectorAug 17Option Exercise75.661,700128,62216,076Aug 19 06:44 PM
BRADBURY DANIELDirectorAug 17Sale208.141,700353,84414,376Aug 19 06:44 PM
FLATLEY JAY TChief Executive OfficerAug 13Option Exercise27.9725,000699,250449,996Aug 13 06:51 PM
FLATLEY JAY TChief Executive OfficerAug 13Sale207.8525,0005,196,268424,996Aug 13 06:51 PM
Bouchard MichelChief Accounting OfficerAug 12Sale205.001,408288,64015,000Aug 13 06:03 PM
WALT DAVID RDirectorAug 11Sale208.695,4971,147,187648,840Aug 12 07:05 PM
EPSTEIN ROBERT SDirectorAug 10Option Exercise51.172,000102,3409,935Aug 12 06:46 PM
EPSTEIN ROBERT SDirectorAug 10Sale212.092,000424,1807,935Aug 12 06:46 PM
WHITFIELD ROY ADirectorAug 05Option Exercise37.244,500167,58018,148Sep 09 07:56 PM
WHITFIELD ROY ADirectorAug 05Sale215.224,500968,49013,648Sep 09 07:56 PM
WALT DAVID RDirectorAug 04Sale215.0310,0002,150,322654,337Aug 06 05:37 PM
WALT DAVID RDirectorAug 04Sale214.992,000429,98746,960Aug 06 05:37 PM
OSTADAN OMEADSr VP Product Dev & OperationsJul 29Option Exercise50.943,510178,78347,673Jul 31 05:29 PM
OSTADAN OMEADSr VP Product Dev & OperationsJul 29Sale217.933,510764,93445,673Jul 31 05:29 PM
WALT DAVID RDirectorJul 28Sale217.2910,0002,172,879664,337Jul 29 08:52 PM
Dadswell CharlesSr VP & General CounselJul 27Sale218.9216736,56041,325Jul 29 08:29 PM
BOWMAN A BLAINEDirectorJul 24Option Exercise39.143,000117,42016,615Jul 24 07:35 PM
BOWMAN A BLAINEDirectorJul 24Sale221.473,000664,40813,615Jul 24 07:35 PM
FLATLEY JAY TChief Executive OfficerJul 23Option Exercise27.9725,000699,250449,996Jul 24 07:19 PM
FLATLEY JAY TChief Executive OfficerJul 23Sale214.8725,0005,371,715424,996Jul 24 07:19 PM
WALT DAVID RDirectorJul 21Sale235.2410,0002,352,449674,337Jul 23 08:34 PM
WALT DAVID RDirectorJul 21Sale235.232,000470,46148,960Jul 23 08:34 PM
Ronaghi MostafaSr VP & CTOJul 17Sale235.001,200282,00041,856Jul 21 08:57 PM
HENRY CHRISTIAN OSr VP & Chief Commercial OfficJul 16Sale229.931,639376,85121,332Jul 17 06:29 PM
Ronaghi MostafaSr VP & CTOJul 15Sale231.581,000231,58042,056Jul 16 06:44 PM
Naclerio NicholasSr VP, Corporate DevelopmentJul 15Sale229.436,5911,512,20521,686Jul 17 05:19 PM
HENRY CHRISTIAN OSr VP & Chief Commercial OfficJul 15Sale229.483,751860,76222,971Jul 17 06:29 PM
WALT DAVID RDirectorJul 14Sale227.3910,0002,273,943684,337Jul 16 06:30 PM
Ronaghi MostafaSr VP & CTOJul 14Sale225.002,000450,00043,056Jul 16 06:44 PM
Stapley MarcSr VP & CFOJul 13Option Exercise36.302,40087,12020,298Jul 14 09:03 PM
Bouchard MichelChief Accounting OfficerJul 13Sale222.751,400311,85016,408Jul 14 08:41 PM
Stapley MarcSr VP & CFOJul 13Sale214.903,000644,70117,298Jul 14 09:03 PM
EPSTEIN ROBERT SDirectorJul 10Option Exercise51.172,000102,3409,935Jul 14 08:28 PM
EPSTEIN ROBERT SDirectorJul 10Sale219.812,000439,6207,935Jul 14 08:28 PM
OSTADAN OMEADSr VP Product Dev & OperationsJul 10Sale219.811,110243,98945,673Jul 14 08:05 PM
FLATLEY JAY TChief Executive OfficerJul 09Option Exercise27.9725,000699,250449,996Jul 10 05:10 PM
FLATLEY JAY TChief Executive OfficerJul 09Sale218.1025,0005,452,477424,996Jul 10 05:10 PM
WALT DAVID RDirectorJul 07Sale220.2210,0002,202,178694,337Jul 08 08:00 PM
WALT DAVID RDirectorJul 07Sale220.162,000440,32950,960Jul 08 08:00 PM
BRADBURY DANIELDirectorJul 06Option Exercise75.661,700128,62216,076Jul 07 02:03 PM
WHITFIELD ROY ADirectorJul 06Option Exercise39.144,500176,13018,148Jul 07 06:10 PM
BRADBURY DANIELDirectorJul 06Sale219.701,700373,48814,376Jul 07 02:03 PM
WHITFIELD ROY ADirectorJul 06Sale218.114,500981,47813,648Jul 07 06:10 PM
WALT DAVID RDirectorJun 30Sale217.6410,0002,176,449704,337Jun 30 05:56 PM
Dadswell CharlesSr VP & General CounselJun 29Sale215.6316034,50142,662Jun 29 06:30 PM
FLATLEY JAY TChief Executive OfficerJun 25Option Exercise32.6325,000815,750449,996Jun 26 04:28 PM
FLATLEY JAY TChief Executive OfficerJun 25Sale220.3425,0005,508,403424,996Jun 26 04:28 PM
BRADBURY DANIELDirectorJun 24Option Exercise75.661,700128,62216,076Jun 24 06:28 PM
HENRY CHRISTIAN OSr VP & Chief Commercial OfficJun 24Sale221.075,0841,123,90926,722Jun 24 05:25 PM
BRADBURY DANIELDirectorJun 24Sale221.231,700376,09814,376Jun 24 06:28 PM
WALT DAVID RDirectorJun 23Sale220.0910,0002,200,942714,337Jun 24 05:01 PM
WALT DAVID RDirectorJun 23Sale220.172,000440,33152,960Jun 24 05:01 PM
HENRY CHRISTIAN OSr VP & Chief Commercial OfficJun 17Sale215.713,751809,11231,806Jun 18 11:38 AM
WALT DAVID RDirectorJun 16Sale215.1410,0002,151,374724,337Jun 18 11:34 AM
Naclerio NicholasSr VP, Corporate DevelopmentJun 15Sale214.336,5901,412,45528,277Jun 15 07:49 PM
Bianchi Paul LSr. VP, Human ResourcesJun 15Sale215.833,408735,54961,123Jun 15 07:53 PM
Stapley MarcSr VP & CFOJun 12Option Exercise36.302,40087,12020,898Jun 15 07:38 PM
Bouchard MichelChief Accounting OfficerJun 12Sale216.111,400302,55415,008Jun 15 07:05 PM
Stapley MarcSr VP & CFOJun 12Sale214.903,000644,70117,898Jun 15 07:38 PM
FLATLEY JAY TChief Executive OfficerJun 11Option Exercise33.8025,000844,875449,996Jun 12 09:49 PM
FLATLEY JAY TChief Executive OfficerJun 11Sale216.4125,0005,410,350424,996Jun 12 09:49 PM
EPSTEIN ROBERT SDirectorJun 10Option Exercise51.172,000102,34011,460Jun 11 05:12 PM
HENRY CHRISTIAN OSr VP & Chief Commercial OfficJun 10Option Exercise69.3410,000693,40045,557Jun 11 06:28 PM
EPSTEIN ROBERT SDirectorJun 10Sale214.242,000428,4809,460Jun 11 05:12 PM
HENRY CHRISTIAN OSr VP & Chief Commercial OfficJun 10Sale214.9410,0002,149,41435,557Jun 11 06:28 PM